XELOX方案治疗晚期结直肠癌87例临床观察

Clinical observation on the effect of XELOX regimen in the treatment of advanced colorectal cancer.

目的探讨卡培他滨联合奥沙利铂（XELOX）方案治疗晚期结直肠癌的近期疗效和毒副反应。方法 87例晚期结直肠癌患者接受XELOX方案化疗（卡培他滨1000mg/m2,po,bid,d1~14;奥沙利铂130mg/m2,静脉点滴,d1）,21d为一个周期。结果完全缓解（CR）7例,部分缓解（PR）41例,有效率（CR＋PR）为55.17%;疾病进展时间（TTP）为6.5个月,生存时间（MST）为12.9个月,1年生存率为53.13%。主要不良反应为骨髓抑制（Ⅰ~Ⅱ度：49例,Ⅲ~Ⅳ度：0例,总计：49例）、胃肠道反应（Ⅰ~Ⅱ度：34例,Ⅲ~Ⅳ度：10例）、外周神经毒性（I~Ⅱ度：21例,Ⅲ~Ⅳ度：0例）、手足综合征（Ⅰ~Ⅱ度：26例,Ⅲ~Ⅳ度：0例）。结论 XELOX作为一线化疗方案治疗晚期结直肠癌安全、有效。

Objective To evaluate the efficacy and toxicity of XELOX regimen for treating advanced colorectal cancer. Methods Eighty-seven patients with advanced colorectal cancer received intravenous infusion of oxaliplatin at the dose of 130 mg/m2 on day 1 and oral administration of capecitabine at 1 000 mg/m2 twice a day on days 1~14. Results Seven patients showed complete response （CR）, and 41 patients showed partial response （PR）. The overall response rate was 55.17%, with a median time to progression of 6.5 months and a median survival time of 12.9 months. The 1-year overall survival rate was 53.13%. The most frequent side effects were bone marrow suppression （49 cases of grade Ⅰ~Ⅱ）, gastrointestinal reactions （34 cases of grade Ⅰ~Ⅱ and 10 cases of grade Ⅲ~Ⅳ）, neural toxicity （21 cases of gradeⅠ~Ⅱ）, and hand-foot syndrome （26 cases of grade Ⅰ~Ⅱ）. Conclusion XELOX regimen was effective and safe as first-line chemotherapy for patients with advanced colorectal cancer.